Expression of HER2/Neu in B-Cell Acute Lymphoblastic Leukemia
- Autores: Sergio Rodriguez Rodriguez, Alan Pomerantz, Roberta Demichelis Gómez, Georgina Barrera Lumbreras, Olga V. Barrales Benítez, Álvaro Aguayo González
- Localización: Revista de investigación clínica, ISSN 0034-8376, ISSN-e 2564-8896, Vol. 68, Nº. 4, 2016, págs. 171-175
- Idioma: inglés
- Enlaces
-
Resumen
Background: The expression of HER2/neu in B-cell acute lymphoblastic leukemia has been reported in previous studies. Objective:
The objective of this research was to study the expression of HER2/neu on the blasts of patients with acute leukemia from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Methods: From June 2015 to February 2016, a HER2/neu monoclonal antibody was added to the panel of antibodies that we routinely use in patients with acute leukemia. An expression of ≥ 30% was considered positive. Results: We studied 33 patients: 19 had de novo leukemia (57.6%), three (9.1%) were in relapse, and in 11 (33.3%) their status could not be specified. Seventeen patients (51.5%) were classified as B-cell acute lymphoblastic leukemia with a median expression of HER2/neu of 0.3% (range 0-90.2). Three patients with B-cell acute lymphoblastic leukemia were positive for HER2/neu: 89.4%, 90.9%, and 62.4%. The first and third patient had de novo B-cell acute lymphoblastic leukemia. The second patient was in second relapse after allogeneic stem cell transplant. All three patients were categorized as high-risk at the time of diagnosis. Conclusions: In the studied Mexican population, we found a positive expression of HER2/neu in 17% of the B-cell acute lymphoblastic leukemia patients, similar to previous studies in which the expression was found in 15-50%. (REV INVES CLIN. 2016;68:171-5)
